The aim of this study was to evaluate the functional and anatomical results of intravitreal ranibizumab in the treatment of diabetic macular edema (DME) with and without serous retinal detachment (SRD).
Setting/Venue
Retrospective
Methods
Fifty-one eyes treated with three intravitreal injections of ranibizumab for DME with and without SRD were retrospectively analyzed. Patients were divided into two groups according to spectral-domain optical coherence tomography (SD-OCT). Group 1 was consisted of 25 DME patients with SRD, Group 2 was consisted of 26 patients without SRD. After three consecutive intravitreal ranibizumab injections, changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed and compared between groups.
Results
The mean age was 64.16 ± 6.43 and, 68.77 ± 7.19 years, respectively (p=0.036). Initial BCVA was 0.55 ± 0.36 logarithm of the minimum angle of resolution (LogMAR), 0.62 ±0.39 LogMAR, respectively (p:0.613). Initial CMT was 548.76 ± 111.62 µm, 446.04 ± 104.10 µm in groups, respectively and it was significantly higher in Group 1 (p=0.001). After three consecutive intravitreal injections of ranibizumab, mean BCVA improved from 0.55 ± 0.36 LogMAR to 0.47 ± 0.30 LogMAR (p=0.281) and CMT decreased from 548.76 ± 111.62 µm to 331.68 ± 165.12 µm (p= 0.000) in Group 1. Mean VA improved from 0.62 ± 0.39 LogMAR to 0.40 ± 0.34 LogMAR (p=0.005) and CMT decreased from 446.04 ± 104.10 µm to 287.25 ± 148.82 µm (p= 0.000) in Group 2. While the decrease in CMT values were similar between the groups, the increase in BCVA was more pronounced in Group 2 after ranibizumab treatment.
Conlusions
Although functional results were not sufficient in DME with SRD; adequate anatomical results could be obtained in DME with and without SRD.